Late HIV Diagnosis and Determinants of Progression to AIDS or Death after HIV Diagnosis among Injection Drug Users, 33 US States, 1996–2004
Authors:
Open Access
- 13 February 2009
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 4 (2) , e4445
Abstract
The timeliness of HIV diagnosis and the initiation of antiretroviral treatment are major determinants of survival for HIV-infected people. Injection drug users (IDUs) are less likely than persons in other transmission categories to seek early HIV counseling, testing, and treatment. Our objective was to estimate the proportion of IDUs with a late HIV diagnosis (AIDS diagnosis within 12 months of HIV diagnosis) and determine the factors associated with disease progression after HIV diagnosis. Using data from 33 states with confidential name-based HIV reporting, we determined the proportion of IDUs aged ≥13 years who received a late HIV diagnosis during 1996–2004. We used standardized Kaplan-Meier survival methods to determine differences in time of progression from HIV to AIDS and death, by race/ethnicity, sex, age group, CD4+ T-cell count, metropolitan residence, and diagnosis year. We compared the survival of IDUs with the survival of persons in other transmission categories. During 1996–2004, 42.2% (11,635) of 27,572 IDUs were diagnosed late. For IDUs, the risk for progression from HIV to AIDS 3 years after HIV diagnosis was greater for nonwhites, males and older persons. Three-year survival after HIV diagnosis was lower for IDU males (87.3%, 95% confidence interval (CI), 87.1–87.4) compared with males exposed through male-to-male sexual contact (91.6%, 95% CI, 91.6–91.7) and males exposed through high-risk heterosexual contact (HRHC) (91.9%, 95% CI, 91.8–91.9). Survival was also lower for IDU females (89.5%, 95% CI, 89.4–89.6) compared to HRHC females (93.3%, 95% CI, 93.3–93.4). A substantial proportion of IDUs living with HIV received their HIV diagnosis late. To improve survival of IDUs, HIV prevention efforts must ensure early access to HIV testing and care, as well as encourage adherence to antiretroviral treatment to slow disease progression.Keywords
This publication has 27 references indexed in Scilit:
- Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapyAIDS, 2007
- Determinants of Progression to AIDS or Death After HIV Diagnosis, United States, 1996 to 2001Annals of Epidemiology, 2006
- Mortality in an Urban Cohort of HIV-Infected and At-Risk Drug Users in the Era of Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2005
- Impact of injecting drug use on the interruption of antiretroviral therapies: Table 1Journal of Epidemiology and Community Health, 2004
- Limited effect of highly active antiretroviral therapy among HIV-positive injecting drug users on the population levelEuropean Journal of Public Health, 2003
- Determinants of survival following HIV-1 seroconversion after the introduction of HAARTThe Lancet, 2003
- Directly Observed Therapy for the Treatment of People with Human Immunodeficiency Virus Infection: A Work in ProgressClinical Infectious Diseases, 2002
- HIV Disease and Advanced AgeDrugs & Aging, 2002
- Effects of HIV counseling and testing on sexual risk behavior: a meta-analytic review of published research, 1985-1997.American Journal of Public Health, 1999
- A generalized kaplan-meier estimator for heterogenous populationsCommunications in Statistics - Theory and Methods, 1988